Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/15125

Title: Role of chemotherapy for advanced/recurrent gastric cancer: An individual-patient-data meta-analysis
Authors: Oba, Koji
Paoletti, Xavier
Bang, Yung-Jue
Bleiberg, Harry
Burzykowski, Tomasz
Fuse, Nozomu
Michiels, Stefan
Morita, Satoshi
Ohashi, Yasuo
Pignon, Jean-Pierre
Rougier, Philippe
Pompidou, Georges
Sakamoto, Junichi
Sargent, Daniel
Sasako, Mitsuru
Shitara, Kohei
Tsuburaya, Akira
Van Cutsem, Eric
Buyse, Marc
Issue Date: 2013
Citation: EUROPEAN JOURNAL OF CANCER, 49 (7), p. 1565-1577
Abstract: We conducted an individual-patient-data meta-analysis of the efficacy of chemotherapy on overall survival (OS) and progression-free survival (PFS) in advanced/recurrent gastric cancer (AGC). Our primary research question was whether the experimental arms of the trials included in the meta-analysis showed a benefit as compared with their corresponding control arms. MEDLINE (up to 2010), Cochrane Central Register of Controlled Trials, National Institutes of Health (NIH) trial registry and proceedings of major oncologic and gastrointestinal cancer meetings were searched. Randomised controlled trials for AGC closed to patient accrual before the end of 2006 were eligible. As of December 2010, individual patient data were available from 22 trials (4245 patients, representing 47% of the targeted data) of 55 eligible trials. The overall comparison of experimental arms with the corresponding control arms showed statistically significant differences in terms of both OS and PFS. Hazard ratio was 0.88 (95% confidence interval 0.82-0.94, P < 0.0001) for OS and 0.81 (0.76-0.88, P < 0.0001) for PFS. The results of the sub-analysis of adding a given chemotherapeutic agent to any chemotherapy confirm the results of the overall analysis, with a hazard reduction of 11% for OS (P < 0.01) and 26% for PFS (P < 0.0001). This meta-analysis of individual patient data shows that the additions of experimental chemotherapeutic agents to pre-existing control or standard regimens have produced a modest improvement in OS and PFS. Median survival remained below 1 year for all investigated chemotherapy regimens and none emerged as a clear standard. (C) 2012 Elsevier Ltd. All rights reserved.
Notes: Hokkaido Univ Hosp, Translat Res & Clin Trial Ctr, Sapporo, Hokkaido 0608648, Japan. INSERM, Inst Curie, U900, Paris, France. Seoul Natl Univ, Coll Med, Seoul, South Korea. Inst Jules Bordet, B-1000 Brussels, Belgium. Hasselt Univ, Diepenbeek, Belgium. Natl Canc Ctr Hosp East, Chiba, Japan. Yokohama City Univ, Yokohama, Kanagawa, Japan. Univ Tokyo, Tokyo, Japan. Inst Gustave Roussy, Villejuif, France. Univ Hosp Europeen Georges Pompidou, AP HP, Paris, France. Nagoya Univ, Nagoya, Aichi 4648601, Japan. Mayo Clin, Rochester, MN USA. Hyogo Coll Med, Nishinomiya, Hyogo, Japan. Univ Hosp Gasthuisberf, Digest Oncol Unit, Louvain, Belgium. Int Inst Drug Dev, Louvain, Belgium.
URI: http://hdl.handle.net/1942/15125
DOI: 10.1016/j.ejca.2012.12.016
ISI #: 000317563600007
ISSN: 0959-8049
Category: A1
Type: Journal Contribution
Validation: ecoom, 2014
Appears in Collections: Research publications

Files in This Item:

Description SizeFormat
artikel472.56 kBAdobe PDF

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.